This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on july 5, 2019.Upon further investigation of the reported event, the following information is new and/or changed: h6 (identification of event problem and evaluation codes 2645, 11, 3331, 4114, 3259, 4307).Patient code: 2645 - no patient involvement.Method code #1: 11 - testing of device from same lot/batch retained by manufacturer.Method code #2: 3331 - analysis of production records.Method code #3: 4114 - device not returned.Results code: 3259 - improper physical structure.Conclusions code: 4307 - cause traced to component failure.The affected sample was not returned for evaluation.A representative retention sample from the possible product/lot number combinations was tested and found to be functioning properly.An engineering investigation and capa have been initiated to determined a definitive root cause.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|